Physician profile
Allanda Williams
NPI 1134780448
$1,291.84
in general payments reported to CMS, 2019-2025
20 companies · $243 in 2025
The $243 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $50.45 · 2021: $128 · 2022: $334 · 2023: $245 · 2024: $292 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $779.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $260.69 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $131.85 | 2020-2025 | Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $124.03 | 2021-2022 | |
| Abbvie INC. | $124.00 | 2022 | |
| Janssen Pharmaceuticals, INC | $106.72 | 2021-2025 | Spravato |
| Merck Sharp & Dohme LLC | $84.16 | 2020-2024 | Gardasil 9, M-M-R II, Gardasil |
| Astrazeneca Pharmaceuticals LP | $82.28 | 2024-2025 | Airsupra, Farxiga |
| Exact Sciences Corporation | $69.90 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $59.99 | 2022-2024 | Quviviq |
| Pfizer INC. | $51.22 | 2023-2024 | |
| Ibsa Pharma INC. | $32.22 | 2023-2025 | Tirosint, Licart, Tirosint |
| Amarin Pharma, INC. | $31.69 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $21.04 | 2022 | |
| Vapotherm INC | $20.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.69 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $16.53 | 2025 | Voquezna |
| Emd Serono, INC. | $16.07 | 2021 | |
| Horizon Therapeutics Plc | $14.35 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.21 | 2024 | Nuzyra |
| Xeris Pharmaceuticals, INC. | $13.35 | 2023 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allanda Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.